Clinical trial
Phase 1/2 Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
NCT05319587 is registered in ClinicalTrials.gov with Moleculin Biotech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1/2 Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
- Lead sponsor
- Moleculin Biotech, Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- September 29, 2022
- Completion date
- August 10, 2023
- Enrollment
- 22 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.